INTRODUCTION: The impact of chemoimmunotherapy (CIT) on immunoglobulin (Ig) quantities in patients with chronic lymphocytic leukemia (CLL) has not been extensively studied. METHODS: We analyzed Ig levels in 45 stable patients with indolent CLL (without indication for treatment) and 87 patients with progressive disease before first-line treatment. Fifty-five patients were evaluated again after the treatment with CIT. RESULTS: We observed significantly lower levels of all Ig classes and subclasses in patients with progressive disease compared to patients with indolent disease. After treatment, median IgA increased from 0.59 g/L to 0.74 g/L (p = 0.0031). In stable patients, lower IgA2 was associated with shorter time to first treatment, although it did not reach statistical significance (p = 0.056). Shorter overall survival was observed in patients with progressive disease and lower IgG2 (p = 0.043). Surprisingly, among the patients with progressive CLL, unmutated IGHV genes were associated with higher levels of IgG, IgG1 and IgM, while TP53 mutation and/or 17p deletion were associated with higher levels of IgA and IgA1. CONCLUSIONS: CIT may lead to increase in IgA levels. Hypogammaglobulinemia is more common in patients with progressive CLL and unmutated IGHV or TP53 dysfunction.

4th Department of Internal Medicine Hematology University Hospital Hradec Kralove Hradec Kralove Czech Republic

Faculty of Medicine in Hradec Kralove Charles University Hradec Kralove Czech Republic

Institute of Clinical Immunology and Allergology University Hospital Hradec Kralove Hradec Kralove Czech Republic

Zobrazit více v PubMed

Panovská A, Doubek M, Brychtová Y, Mayer J. Chronic lymphocytic leukemia and focusing on epidemiology and management in everyday hematologic practice: recent data from the Czech Leukemia Study Group for Life (CELL). Clin Lymphoma Myeloma Leuk. 2010;10(4):297‐300. doi:10.3816/CLML.2010.n.061 PubMed DOI

Van Bockstaele F, Verhasselt B, Philippé J. Prognostic markers in chronic lymphocytic leukemia: a comprehensive review. Blood Rev. 2009;23(1):25‐47. doi:10.1016/j.blre.2008.05.003 PubMed DOI

Dasanu CA, Alexandrescu DT. Risk for second nonlymphoid neoplasms in chronic lymphocytic leukemia. MedGenMed. 2007;9(4):35 Accessed November 15, 2007. PubMed PMC

Wadhwa PD, Morrison VA. Infectious complications of chronic lymphocytic leukemia. Semin Oncol. 2006;33(2):240‐249. doi:10.1053/j.seminoncol.2005.12.013 PubMed DOI

Hudson RP, Wilson SJ. Hypogammaglobulinemia and chronic lymphatic leukemia. Cancer. 1960;13:200‐204. PubMed

Mauro FR, Morabito F, Vincelli ID, et al. Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage a chronic lymphocytic leukemia. Leuk Res. 2017;57:65‐71. doi:10.1016/j.leukres.2017.02.011 PubMed DOI

Parikh SA, Leis JF, Chaffee KG, et al. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: natural history, clinical correlates, and outcomes. Cancer. 2015;121(17):2883‐2891. doi:10.1002/cncr.29438 PubMed DOI PMC

Singh N, Mott SL, Sutamtewagul G, et al. Prevalence and the impact of hypogammaglobulinemia in newly diagnosed chronic lymphocytic lymphoma patients. EJHaem. 2020;1(2):537‐544. doi:10.1002/jha2.95 PubMed DOI PMC

Rozman C, Montserrat E, Viñolas N. Serum immunoglobulins in b‐chronic lymphocytic leukemia natural history and prognostic significance. Cancer. 1988;61(2):279‐283. PubMed

Andersen MA, Vojdeman FJ, Andersen MK, et al. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia is a predictor of early death. Leuk Lymphoma. 2016;57(7):1592‐1599. doi:10.3109/10428194.2016.1142082 PubMed DOI

Shvidel L, Tadmor T, Braester A, et al. Serum immunoglobulin levels at diagnosis have no prognostic significance in stage a chronic lymphocytic leukemia: a study of 1113 cases from the Israeli CLL study group. Eur J Haematol. 2014;93(1):29‐33. doi:10.1111/ejh.12290 PubMed DOI

Ishdorj G, Streu E, Lambert P, et al. IgA levels at diagnosis predict for infections, time to treatment, and survival in chronic lymphocytic leukemia. Blood Adv. 2019;3(14):2188‐2198. doi:10.1182/bloodadvances.2018026591 PubMed DOI PMC

Korona‐Glowniak I, Grywalska E, Grzegorczyk A, Roliński J, Glowniak A, Malm A. Bacterial colonization in patients with chronic lymphocytic leukemia and factors associated with infections and colonization. J Clin Med. 2019;8(6):861. doi:10.3390/jcm8060861 PubMed DOI PMC

Andersen MA, Eriksen CT, Brieghel C, et al. Incidence and predictors of infection among patients prior to treatment of chronic lymphocytic leukemia: a Danish nationwide cohort study. Haematologica. 2018;103(7):e300‐e303. doi:10.3324/haematol.2017.182006 PubMed DOI PMC

Crassini KR, Zhang E, Balendran S, et al. Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment‐free and overall survival in chronic lymphocytic leukaemia. Br J Haematol. 2018;181:97‐101. doi:10.1111/bjh.15146 PubMed DOI

Corbingi A, Innocenti I, Tomasso A, et al. Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia. Br J Haematol. 2020;190(6):901‐908. doi:10.1111/bjh.16975 PubMed DOI

Francis S, Karanth M, Pratt G, et al. The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia. Cancer. 2006;107(5):1023‐1033. doi:10.1002/cncr.22094 PubMed DOI

Hensel M, Kornacker M, Yammeni S, Egerer G, Ho AD. Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia. Br J Haematol. 2003;122(4):600‐606. doi:10.1046/j.1365-2141.2003.04497.x PubMed DOI

Visentin A, Compagno N, Cinetto F, et al. Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy. Haematologica. 2015;100(12):e515‐e518. doi:10.3324/haematol.2015.126763 PubMed DOI PMC

Freeman JA, Crassini KR, Best OG, et al. Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2013;54(1):99‐104. doi:10.3109/10428194.2012.706285 PubMed DOI

Dearden C. Disease‐specific complications of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2008;2008:450‐456. doi:10.1182/asheducation-2008.1.450 PubMed DOI

Sampalo A, Navas G, Medina F, Segundo C, Cámara C, Brieva JA. Chronic lymphocytic leukemia B cells inhibit spontaneous Ig production by autologous bone marrow cells: role of CD95‐CD95L interaction. Blood. 2000;96(9):3168‐3174. PubMed

Kay NE, Perri RT. Evidence that large granular lymphocytes from B‐CLL patients with hypogammaglobulinemia down‐regulate B‐cell immunoglobulin synthesis. Blood. 1989;73(4):1016‐1019. PubMed

Criado I, Muñoz‐Criado S, Rodríguez‐Caballero A, et al. Host virus and pneumococcus‐specific immune responses in high‐count monoclonal B‐cell lymphocytosis and chronic lymphocytic leukemia: implications for disease progression. Haematologica. 2017;102(7):1238‐1246. doi:10.3324/haematol.2016.159012 PubMed DOI PMC

Vitale C, Boccellato E, Comba L, et al. Impact of immune parameters and immune dysfunctions on the prognosis of patients with chronic lymphocytic leukemia. Cancer. 2021;13(15):3856. doi:10.3390/cancers13153856 PubMed DOI PMC

Smolej L, Vodárek P, Écsiová D, Šimkovič M. Chemoimmunotherapy in the first‐line treatment of chronic lymphocytic leukaemia: dead yet, or alive and kicking? Cancer. 2021;13(13):3134. Accessed January 23, 2021. doi:10.3390/cancers13133134 PubMed DOI PMC

Keating MJ, O'Brien S, Lerner S, et al. Long‐term follow‐up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 1998;92(4):1165‐1171. PubMed

Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4079‐4088. doi:10.1200/JCO.2005.12.051 PubMed DOI

Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk. 2013;13(2):106‐111. doi:10.1016/j.clml.2012.11.011 PubMed DOI PMC

Czuczman MS, Koryzna A, Mohr A, et al. Rituximab in combination with fludarabine chemotherapy in low‐grade or follicular lymphoma. J Clin Oncol. 2005;23(4):694‐704. doi:10.1200/JCO.2005.02.172 PubMed DOI

Roberts DM, Jones RB, Smith RM, et al. Rituximab‐associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi‐system autoimmune disease. J Autoimmun. 2015;57:60‐65. doi:10.1016/j.jaut.2014.11.009 PubMed DOI

Hiddemann W, Barbui AM, Canales MA, et al. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. J Clin Oncol. 2018;36(23):2395‐2404. doi:10.1200/JCO.2017.76.8960 PubMed DOI

Grigg A, Dyer MJ, Díaz MG, et al. Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma. Haematologica. 2017;102(4):765‐772. doi:10.3324/haematol.2016.152272 PubMed DOI PMC

Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32‐42. doi:10.1056/NEJMoa1215637 PubMed DOI PMC

O'Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open‐label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15(1):48‐58. doi:10.1016/S1470-2045(13)70513-8 PubMed DOI PMC

Sun C, Tian X, Lee YS, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 2015;126(19):2213‐2219. doi:10.1182/blood-2015-04-639203 PubMed DOI PMC

Barrientos JC, O'Brien S, Brown JR, et al. Improvement in parameters of hematologic and immunologic function and patient well‐being in the phase III RESONATE study of ibrutinib versus ofatumumab in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. Clin Lymphoma Myeloma Leuk. 2018;18(12):803. doi:10.1016/j.clml.2018.08.007 PubMed DOI PMC

Cassin R, Visentin A, Giannarelli D, et al. Increase of immunoglobulin a during ibrutinib therapy reduces infection rate in chronic lymphocytic leukemia patients. Hematol Oncol. 2021;39(1):141‐144. doi:10.1002/hon.2814 PubMed DOI

Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745‐2760. doi:10.1182/blood-2017-09-806398 PubMed DOI

Eichhorst B, Fink AM, Bahlo J, et al. First‐line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open‐label, randomised, phase 3, non‐inferiority trial. Lancet Oncol. 2016;17(7):928‐942. doi:10.1016/S1470-2045(16)30051-1 PubMed DOI

Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101‐1110. doi:10.1056/NEJMoa1313984 PubMed DOI

Hillmen P, Gribben JG, Follows GA, et al. Rituximab plus chlorambucil as first‐line treatment for chronic lymphocytic leukemia: final analysis of an open‐label phase II study. J Clin Oncol. 2014;32(12):1236‐1241. doi:10.1200/JCO.2013.49.6547 PubMed DOI PMC

Nosari A. Infectious complications in chronic lymphocytic leukemia. Mediterr J Hematol Infect Dis. 2012;4(1):e2012070. doi:10.4084/MJHID.2012.070 PubMed DOI PMC

Pasiarski M, Rolinski J, Grywalska E, et al. Antibody and plasmablast response to 13‐valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients—preliminary report. PLoS One. 2014;9(12):e114966. doi:10.1371/journal.pone.0114966 PubMed DOI PMC

Svensson T, Kättström M, Hammarlund Y, et al. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia a randomized study by the Swedish CLL group. Vaccine. 2018;36(25):3701‐3707. doi:10.1016/j.vaccine.2018.05.012 PubMed DOI

Burger JA, Sivina M, Jain N, et al. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019;133(10):1011‐1019. doi:10.1182/blood-2018-10-879429 PubMed DOI PMC

Solman IG, Blum LK, Hoh HY, et al. Ibrutinib restores immune cell numbers and function in first‐line and relapsed/refractory chronic lymphocytic leukemia. Leuk Res. 2020;97:106432. doi:10.1016/j.leukres.2020.106432 PubMed DOI

Puzzolo MC, Del Giudice I, Peragine N, et al. TH2/TH1 shift under ibrutinib treatment in chronic lymphocytic leukemia. Front Oncol. 2021;11:637186. doi:10.3389/fonc.2021.637186 PubMed DOI PMC